Background The role of platinum-based neoadjuvant chemotherapy in triple-negative breast
cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines …

Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone
agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …

Simple Summary Breast cancer is the most common cancer affecting women under 40 years
of age worldwide, with an increasing number of cases diagnosed each year. Despite this …

PURPOSE Many patients and physicians remain concerned about the potential detrimental
effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and …

Breast cancer is the most common cancer diagnosis in women aged less than 40 years and
the second most common cause of cancer death in this age group. Global rates of young …

Abstract Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen
and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were …

Breast cancer risk associated with germline likely pathogenic/pathogenic variants (PV)
varies by gene, often by penetrance (high> 50% or moderate 20–50%), and specific locus …

Purpose Women under 40 years old are at increased risk for developing human epidermal
growth factor receptor 2 (HER2) positive or triple negative subtype and more advanced …